Sanifit announces that Phase 2b CaLIPSO trial of SNF472 met its primary endpoint

NEXT STORY
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
PREV STORY
Curetis To Attend Key Conferences in the Fourth Quarter of 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Quantum Materials Announces QDX™ HealthID to Support Back-to-Work “Immunization Passport” Programs

author_avatar
NASDAQ Market News

Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19

author_avatar
NASDAQ Market News

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab, in Patients with Advanced Endometrium or Colorectal Tumors

author_avatar
NASDAQ Market News